re: CLDX
Dr. Linda Vahdat was asked what kind of response she would have expected from the drug in this patient population. She said that she wouldn't have expected any response. So she is excited by the results in these heavily pre-treated patients (up to seven different types of pre-treatment).
Dr. Vahdat was further asked if she would use the drug earlier in therapy. Her response was "That would be a no-brainer," because nothing else works in these patients.
I'm not sure why the stock is down so much in AH, but to my uneducated eye, it looks like another ECYT-type of response to the trial results. In other words, the Street doesn't get it...yet. But I'll defer to Peter, jq, p3, PGS and others on this one.
Bladerunner
Market Data 
Markets 
AI
